Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127861031 | 12786103 | 1 | I | 2006 | 20160920 | 20160927 | 20160927 | EXP | DK-DKMA-ADR 23654633 | DK-PFIZER INC-2016443509 | PFIZER | 44.00 | YR | F | Y | 0.00000 | 20160927 | OT | DK | DK |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127861031 | 12786103 | 1 | PS | VENLAFAXINE HCL | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | DOSERING VARIERENDE | U | 20699 | PROLONGED-RELEASE CAPSULE | ||||||||
| 127861031 | 12786103 | 2 | SS | VENLAFAXINE HCL | VENLAFAXINE HYDROCHLORIDE | 1 | 37.5 MG, UNK | U | 20699 | 37.5 | MG | PROLONGED-RELEASE CAPSULE | |||||||
| 127861031 | 12786103 | 3 | SS | VENLAFAXINE HCL | VENLAFAXINE HYDROCHLORIDE | 1 | 3 DF, DAILY | U | 20699 | 3 | DF | PROLONGED-RELEASE CAPSULE | |||||||
| 127861031 | 12786103 | 4 | SS | VENLAFAXINE HCL | VENLAFAXINE HYDROCHLORIDE | 1 | 225 MG, DAILY | U | 20699 | 225 | MG | PROLONGED-RELEASE CAPSULE | |||||||
| 127861031 | 12786103 | 5 | SS | VENLAFAXINE HCL | VENLAFAXINE HYDROCHLORIDE | 1 | DOSE REDUCED | U | 20699 | PROLONGED-RELEASE CAPSULE | |||||||||
| 127861031 | 12786103 | 6 | C | LAMICTAL | LAMOTRIGINE | 1 | 25 MG, DAILY | 0 | 25 | MG | |||||||||
| 127861031 | 12786103 | 7 | C | MIRTAZAPINE. | MIRTAZAPINE | 1 | Oral | AT NIGHT | 0 | ||||||||||
| 127861031 | 12786103 | 8 | C | MIRTAZAPINE. | MIRTAZAPINE | 1 | 30 MG, UNK | 0 | 30 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127861031 | 12786103 | 1 | Depression |
| 127861031 | 12786103 | 6 | Mental disorder |
| 127861031 | 12786103 | 7 | Depression |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127861031 | 12786103 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127861031 | 12786103 | Ankle fracture | |
| 127861031 | 12786103 | Balance disorder | |
| 127861031 | 12786103 | Blood folate decreased | |
| 127861031 | 12786103 | Conjunctivitis | |
| 127861031 | 12786103 | Dental caries | |
| 127861031 | 12786103 | Dry mouth | |
| 127861031 | 12786103 | Fall | |
| 127861031 | 12786103 | Hypersensitivity | |
| 127861031 | 12786103 | Hypoaesthesia | |
| 127861031 | 12786103 | Lacrimation increased | |
| 127861031 | 12786103 | Muscular weakness | |
| 127861031 | 12786103 | Nervous system disorder | |
| 127861031 | 12786103 | Pain | |
| 127861031 | 12786103 | Paraesthesia | |
| 127861031 | 12786103 | Polyneuropathy | |
| 127861031 | 12786103 | Psychotic disorder | |
| 127861031 | 12786103 | Restless legs syndrome | |
| 127861031 | 12786103 | Salivary hypersecretion | |
| 127861031 | 12786103 | Thyroid disorder | |
| 127861031 | 12786103 | Tooth fracture | |
| 127861031 | 12786103 | Tremor | |
| 127861031 | 12786103 | Vision blurred | |
| 127861031 | 12786103 | Visual acuity reduced | |
| 127861031 | 12786103 | Vitamin B12 deficiency |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127861031 | 12786103 | 1 | 200405 | 20140504 | 0 | |
| 127861031 | 12786103 | 2 | 20091021 | 0 | ||
| 127861031 | 12786103 | 4 | 20091119 | 0 | ||
| 127861031 | 12786103 | 5 | 20110418 | 0 | ||
| 127861031 | 12786103 | 6 | 2004 | 201309 | 0 | |
| 127861031 | 12786103 | 7 | 20110418 | 201405 | 0 | |
| 127861031 | 12786103 | 8 | 20111205 | 0 |